A Study Assessing the Safety and Efficacy of Adding Ipatasertib to Paclitaxel Treatment in Participants With Breast Cancer That Has Spread Beyond the Initial Site, and the Cancer Does Not Have Certain Hormonal Receptors

Inclusion Criteria:

- Histologically documented triple-negative adenocarcinoma of the breast that is
inoperable locally advanced or metastatic and is not amenable to resection with
curative intent

- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

- Availability of a representative formalin-fixed, paraffin-embedded (FFPE) tumor
specimen, required prior to randomization

- Measurable disease, according to the RECIST v1.1

- Adequate hematologic and organ function within 14 days before the first study
treatment

- For female participants of childbearing potential, agreement (by both participant and
partner) to use an effective form of contraception for the duration of the study and
for 6 months after last dose of study treatment

Exclusion Criteria:

- Any previous therapy, including chemotherapy or hormonal or targeted therapy, for
inoperable locally advanced or metastatic triple-negative adenocarcinoma of the
breast. Participants may have received prior neoadjuvant or adjuvant chemotherapy
and/or radiation treatment for locally advanced triple negative adenocarcinoma,
provided all treatments were completed greater than or equal to (>/=) 6 months prior
to Cycle 1 Day 1. Locally recurrent disease must not be amenable to resection with
curative intent

- Any radiation treatment to metastatic site within 28 days of Cycle 1, Day 1

- Known Human Epidermal Growth Factor Receptor 2 (HER2) positive, erythrocyte receptor
(ER) positive, or progesterone receptor (PR) positive breast cancer

- Previous therapy with Akt, PI3K, and/or mTOR inhibitors

- Major surgical procedure, open biopsy, or significant traumatic injury within 30 days
prior to Cycle 1, Day 1 or anticipation of need for a major surgical procedure during
the course of the study

- Known presence of the brain or spinal cord metastasis, as determined by computed
tomography (CT) or magnetic resonance imaging (MRI) evaluation during screening or
prior radiographic assessments